Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)

Next Previous
Trial Profile

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumasiran (Primary)
  • Indications Primary hyperoxaluria type 1
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-C
  • Sponsors Alnylam Pharmaceuticals

Most Recent Events

  • 02 Jul 2025 According to an Alnylam Pharmaceuticals media release, OXLUMO is now reimbursed in Canada for the treatment of primary hyperoxaluria type 1 (PH1) in pediatric and adult patients. The positive recommendation for reimbursement was supported by results of the ILLUMINATE clinical studies.
  • 01 Feb 2023 Results published in the American Journal of Kidney Diseases
  • 27 Oct 2022 According to an Alnylam Pharmaceuticals media release, the company received approval from the European Medicines Agency (EMA) of a Type II variation to include the ILLUMINATE-C data in the label.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top